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Abstract
Activation of the phosphoinositide 3-kinase pathway is commonly observed in human prostate cancer. Loss of func-
tion of phosphatase and tensin homolog (PTEN) is associated with the activation of AKT and mammalian target of
rapamycin (mTOR) in many cancer cell lines as well as in other model systems. However, activation of mTOR is also
dependent of kinases other than AKT. Here, we show that activation of mTOR is not dependent on AKT in a prostate-
specific PTEN-deficient mouse model of prostate cancer. Pathway bifurcation of AKT and mTOR was noted in
both mouse and human prostate tumors. We demonstrated for the first time that cotargeting mTOR and AKT with
ridaforolimus/MK-8669 and M1K-2206, respectively, delivers additive antitumor effects in vivo when compared to
single agents. Our preclinical data suggest that the combination of AKT and mTOR inhibitors might be more effec-
tive in treating prostate cancer patients than current treatment regimens or either treatment alone.
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Introduction
Prostate cancer, the third most common cause of cancer-related deaths
in men, is particularly high in developed countries and the prevalence is
now also increasing in developing nations [1]. Prostate cancer is the
second most frequently diagnosed cancer in men in the United States
with more than two million currently suffering from this disease.
Although the death rate from prostate cancer is decreasing with the
advent of early diagnosis, surgery, radiotherapy, and hormonal and
chemotherapies, it still remains one of the leading causes of cancer-
related death in men.
The androgen receptor (AR) signaling pathway plays a central role in
the normal development and growth of the prostate gland, as well as the
abnormal growth of prostate cancer (reviewed in [2]). The primary clin-
ical strategy for prostate cancer treatment is to suppress AR signaling
by androgen deprivation through castration, estrogen, antiandrogens,
or their combination (reviewed in [3]). Androgen ablation by either
surgical castration or luteinizing hormone–releasing hormone (LHRH)
analogue treatments strongly inhibits the growth of localized advanced
cancer by eliminating circulating testosterone [4,5]. Unfortunately,
within a few years after androgen ablation therapy, most patients
experience resurgence of aggressive disease that is refractory to anti-
androgen therapy (reviewed in [6]). The mechanism of acquired resis-
tance to antiandrogens remains unclear, yet emerging evidence suggests a
central role for the phosphoinositide 3-kinase (PI3K) pathway [7–9]. We
recently demonstrated that activation of the PI3K pathway is indepen-
dent of AR signaling and combining a mammalian target of rapamycin
(mTOR) inhibitor and AR antagonist displays significantly greater anti-
tumor effect in an androgen-dependent model of prostate cancer [10].
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The PI3K pathway plays an important role in regulating several
cellular functions including cell growth, proliferation, differentiation,
and survival. Loss or functional alteration of the tumor suppressor gene
PTEN activates downstream PI3K signaling, resulting in increased cell
proliferation and survival [11–15]. More than 20% of primary human
prostate cancer is associated with the deletion or functional loss of
PTEN, whereas more than 50% of human metastatic prostate cancer
specimens harbor biallelic loss of this gene, suggesting a central role for
phosphatase and tensin homolog (PTEN) loss in the lethal form of the
disease [16–20]. Conventional deletion of both alleles of Pten leads to
embryonic lethality in mice [21,22], whereas heterozygous Pten-null mice
develop prostate intraepithelial neoplasia. These mice have been crossed
with a number of other genetically engineered mice for further en-
hancement of the tumor phenotype (reviewed in Majumder and Sellers
[23]). Loss-of-function mutations or lowered expression of PTEN
increases the activity of important downstream targets of PI3K, such
as AKT, in various cell lines and engineered mouse models (reviewed
in [24,25]). Activation of AKT1 in the prostate alone induces the devel-
opment of PIN but not invasive prostate cancer, whereas activation
of AKT1 in a p27Kip1-null setting as well as prostate-specific deletion
of Pten induces invasive cancer in mice [26–28]. To dissect the role of
different components of the PI3K pathway signaling network, we have
used a genetically engineered mouse model where PtenloxP/loxP mice
(loxP—locus of X-over P1, [29]) were crossed with ARR2-Pb-Cre+
(rat probasin promoter with two androgen-responsive regions driving the
Cre recombinase) transgenic mice [30]. These mice spontaneously devel-
op prostate tumors that recapitulate most human prostate cancer char-
acteristics [28]. AKT and mTOR, two important kinases of the PI3K
pathway, are activated as measured by phosphorylation in this model.
It has been reported that inhibition of mTOR by rapamycin analogues
showed antitumor effects in preclinical models [10,13,14,27,31]. How-
ever, the negative feedback frommTOR inhibition on AKTmight be an
important factor to consider for treating PTEN-null tumors with rapa-
logs [30–32]. Here, we demonstrate that MK-2206, a small molecule
inhibitor of AKT, is as efficacious as anmTOR inhibitor (ridaforolimus/
MK-8669) for treatment of PTEN-null prostate tumors and that
activation of mTOR is not dependent on AKT activity. Using both a
genetically engineered mouse model and a human prostate cancer cell–
based model, we demonstrate a combination benefit of these two
inhibitors. Our findings support the combination of AKT and mTOR
inhibitors for treatment of PTEN-null prostate cancer in patients.
Materials and Methods
Animals
A conditional Pten-deficient model of prostate cancer (Ptenloxp/loxp/
Pb-Cre4) in which Pten is homozygously deleted in the prostate gland
because of prostate-specific expression of Cre recombinase [28] was
used for these studies. This model was licensed from Dr Hong Wu’s
laboratory at the University of California (Los Angeles, CA). Both
founder lines, the ARR2Probasin-Cre (C+) transgenic mice ([33]; on
C57BL/6xDBA2 background) and the PtenLoxp/Loxp mice (on a 129/
Balb/c background), were maintained using our contract facility. The
heterozygous PtenLoxp/+;C/+ males were bred to PtenLoxp/Loxp females to
obtain the PtenLoxp/loxp;C/+ genotype. Male PtenLoxp/loxp;C/+ mice
between 36 and 46 weeks of age were used for experiments. Mice were
using an isolated barrier unit system on woodchip bedding and fed
standard rodent chow ad libitum.
Treatment
Animals were prescreened by three-dimensional (3D) ultrasound
imaging to obtain a baseline tumor volume for enrollment and were
randomized into groups based on tumor volumes. Ten animals were
treated with an orally active AKT inhibitor (MK-2206) [34] at a
dose of either 120 mg/kg or 240 mg/kg thrice a week (Monday,
Wednesday, and Friday), and other 10 animals were kept as controls
(vehicle treated). Mice were imaged weekly. Tumor-bearing mice were
also treated intraperitoneally with an mTOR inhibitor (ridaforolimus)
[35] at 1.0 mg/kg, once a day (Monday to Friday), or with the combi-
nation of MK-2206 and ridaforolimus at their above indicated doses,
or by 0.5% methylcellulose + normal saline (placebo) for 9 weeks.
Prostate Tumor Measurement
Prostate tumors were imaged using a 3D ultrasound imaging sys-
tem Vevo770 (VisualSonics, Toronto, Canada). 3D images were re-
constructed from 2D section images using the Vevo770 system
software following acquisition. Tumor volumes were determined us-
ing the 3D Quantify Version 3.5 software (Robarts Research Institute,
London, Canada) as described [10]. For each study, animals were
randomized into groups based on their baseline tumor volumes mea-
sured by ultrasound imaging and animals were imaged weekly for 9 to
10 weeks. All animal procedures were reviewed and approved by the
Merck Research Laboratories-Boston Institutional Animal Care and
Use Committee.
Endpoint Tumor Assessment
Mice were killed using CO2, and the entire tumors were collected
and weighed. Animals were killed, and tumor samples were collected
when tumor volumes reached 10% of body weight before study
termination. Tumor samples were collected for histologic and bio-
chemical analyses.
Histologic and Immunohistochemical Analyses
Formalin-fixed paraffin-embedded tissues were sectioned at 5-μm
thickness. Tissue sections were stained with hematoxylin and eosin
(Fisher Scientific, Waltham, MA) and analyzed for cell proliferation
[bromodeoxyuridine (BrdU), 1:500 (BD Biosciences, San Jose, CA);
Ki-67, 1:500, Clone SP6 (Lab Vision, Kalamazoo, MI)]. The status of
phospho-S6 ribosomal protein (1:75; Cell Signaling Technology, Inc,
Danvers, MA) and p-AKT (S473) (1:50; Cell Signaling Technology,
Inc) were also measured. Automated staining was performed using
the ChromoMap Kit on the Discovery XT (Ventana Medical System,
Inc, Tucson, AZ) under standard conditions as described [36].
Cell Line
Human prostate cancer cell line (LNCaP) was cultured in RPMI
with 10% fetal bovine serum, 1% glutamine, penicillin/streptomycin,
and 50 μM β-mercaptoethanol at 37°C under 5% CO2. To inhibit
AKT signaling, we plated cells at 1 × 106 in a 10-cm dish in the pres-
ence of either MK-2206 at 0.1, 0.5, or 1 μM, or ridaforolimus at 0.1,
0.5, or 1.0 μM, or a combination of MK-2206 and ridaforolimus.
Mock-treated cells were cultured with DMSO at a final concentration
of 0.01%. Cell growth was measured by ATPlite assay as per manufac-
tured kits (PerkinElmer Life Sciences, Waltham, MA). Statistical analy-
sis to determine highest single-agent response (HSA) and confidence
interval (CI) values was performed.
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Western Blot Analysis and Reverse Phase Protein Array
Tumor samples or cells were collected, flash frozen in liquid nitrogen,
and stored at −80°C until processed. Frozen samples were thawed in
cold RIPA lysis buffer [0.5 M Tris-HCl (pH 7.4), 1.5 M NaCl, 2.5%
deoxycholic acid, 10% NP-40, and 10 mM EDTA; Upstate USA, Inc,
Billerica, MA] containing complete protease inhibitor cocktail (Roche,
Indianapolis, IN). Protein concentrations in cell and tissue lysates were
determined by the Bicinchoninic Acid Protein Assay Kit (Pierce Biotech-
nology, Rockford, IL) according to the manufacturer’s instructions.
Twenty nanoliters of denatured lysates from each mice was immobilized
onto nitrocellulose-backed glass slides and probed with validated
corresponding phosphoepitope-specific antibodies for the said analyte.
Arrays were developed with a 3,3′-diaminobenzidine tetrahydrochloride
chromogen after which intensity values were measured by ImageQuant
for each sample. Phospho-AKT (S473 and T308), phospho-S6RP
(S235/236), total AKT, and total S6RP were measured. All proteins
were detected by resolving proteins on criterion 4 to 15% Tris-HCl
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (Bio-Rad
Laboratories, Hercules, CA) and blotted onto nitrocellulose mem-
brane. Residual binding sites were blocked by 5% nonfat dry milk
and blotted with antibodies against phospho-AKT (S473 and T308;
1:1000), phospho-S6RP (1:1000; Cell Signaling Technology, Inc), and
tubulin (1:1000; Abcam Inc, Cambridge, MA). Detection of protein
bands was performed using SuperSignal West Pico and Femto Chemi-
luminescent Substrate (Pierce Biotechnology) after incubation with
the HRP-conjugated secondary antibody (1:5000; Jackson Immuno-
Research Laboratories, Inc, West Grove, PA).
mRNA Microarray Expression Analysis
Tumors were dissected from Pten wild-type and Pten-null mice at
the age of 6, 10, 14, 21, 30, and 36 weeks. Tumor or normal prostate
samples for RNA analysis were snap frozen in 1ml of Triazol (Invitrogen,
Grand Island, NY) per 100 mg of tissue. RNA was extracted using a
RNeasy midi kit (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions but with additional treatment with RNase-free
DNAse Set (Qiagen) before elution. cDNA was synthesized using the
high-capacity archive kit (Applied Biosystems, Carlsbad, CA). mRNA
and microarray studies were conducted as previously described [37].
Statistical Analysis
A repeated measures analysis of variance followed by Dunnett’s
multiple comparison tests were performed for longitudinal studies
and Student’s t test was conducted to evaluate statistically significant
differences between groups for the endpoint analyses.
Results
Prostate Tumors in PtenLoxp/Loxp;C+ Mice Are Sensitive to
AKT Inhibitor
Activation of AKT either through loss-of-function tumor suppressor
gene PTEN or by the activation of PI3K has been identified in human
prostate cancer. Phosphorylation of AKT occurs at both S473 and
T308 sites in PTEN-deleted mouse models of prostate cancer. Acti-
vation of AKT, along with other downstream targets of PTEN, is
observed in this model [10,28]. To determine whether this model is
dependent on AKT, we have treated tumor-bearing mice with an allo-
steric inhibitor of AKT (MK-2206). Twenty mice with tumor volumes
ranging from 300 to 400 mm3 (ages ranged from 36 to 46 weeks old)
were randomly assigned to two groups. One group was treated by 0.5%
methylcellulose (placebo), and the remaining mice were treated with
MK-2206 at the dose of 240 mg/kg thrice a week. Mice were imaged
weekly by ultrasound following enrollment into the study to monitor
tumor volume. Within the first 3 weeks following treatment, we
observed no difference in tumor growth between placebo and AKT
inhibitor (Figure 1A). By week four, tumor volumes in the MK-
2206–treated mice were significantly smaller compared to the placebo
controls (Figure 1A). Our results show a drop of tumor volume in con-
trol group due to death of two large tumor-bearing mice. Four hours
after the last dose at 11 weeks, mice were killed and tumor weight was
measured. Data showed a tumor net weight reduction along with a
Figure 1. PTEN-deficient tumors are sensitive to AKT inhibition. (A) Tumor response to AKT inhibitor MK-2206. Prostate tumors in PTEN-
deficient mice were imaged, and the mice were randomized into two groups (n = 10/group) based on tumor volume (∼400 mm3). Mice
in group 1 underwent placebo treatment and those in group 2 were treated with MK-2206 at a dose of 240 mg/kg thrice a week. Tumors
were imaged and volume was measured weekly for 11 weeks and represented as mean ± SEM. (B) Mice were killed; tumors were
dissected and weight wasmeasured. Significant (P≤ 0.05) tumor growth progressionwas observedwhenmicewere treated withMK-2206
compared to the corresponding placebo-treated mice.
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significant reduction in ultrasound-measured volume following MK-
2206 treatment (Figure 1B). These data demonstrate that AKT plays
a significant role in tumor growth progression in this model of prostate
cancer.However, AKT inhibition alone was not sufficient to completely
suppress, suggesting other PI3K pathway nodes and/or other oncogenic
signaling networks might also play a critical role in tumor maintenance
and growth.
Activation of the mTOR Pathway Is Independent of AKT in a
PTEN-Deficient Model of Prostate Cancer
Loss of function of PTEN is associated with activation of both
AKT and mTOR kinases evidenced by increased phosphorylation
of both AKT and S6RP, a downstream target of mTOR kinase in these
tumors ([10,28], and data not shown). However, it is not clear whether
the activation of mTOR downstream signaling is due to activation of
AKT. Inhibition of AKT phosphorylation at S473 and T308 was noted
in tumors treated with MK-2206 (Figure 2A, upper panel and data not
shown). Surprisingly, tumor sections stained with p-S6RP indicate no
inhibition of the mTOR signaling network when tumors were treated
with MK-2206 (Figure 2A, lower panel ). Similarly, immunoblots
showed that MK-2206 had no effect on the phosphorylation status of
S6RP while completely blocking p-AKT, whereas mTOR inhibitor
completely inhibited p-S6RP with no effect on p-AKT (Figure 2B ).
To determine the quantitative inhibition of phosphorylation with both
Figure 2. AKT inhibition does not alter the activation of mTOR. Tumor-bearing mice were surgically treated with inhibitors of AKT at
240 mg/kg or mTOR at 1 mg/kg for 9 weeks and harvested 4 hours after the last dose. (A) Tumor sections from 0.5% methylcellulose
(placebo), inhibitor of AKT (MK-2206) (upper panel), and mTOR inhibitor treatment (lower panel) were stained with antibody against p-S6RP
and p-AKT. These are representative pictures of four mice per group. Scale bar is 50 μm. (B) Fresh tissues were lysed and total protein
was isolated. Protein was separated by gel electrophoresis, blotted onto membrane, and hybridized with antibody against p-AKT (S473)
and p-S6RP(S235/236). Tubulin was used as a loading control. (C) Reverse phase protein array analysis of tumor lysates for p-AKT and total
AKT from MK-2206–treated samples (left panel), from mTOR inhibitor–treated samples (middle panel), and p-S6RP and total S6RP were
performed from ridaforolimus or MK-2206–treated tumors (right panel). Results are represented in a standard box blot format in which
the boundaries of the box are the smallest and largest intensity observations, and the notch denotes the median.
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AKT and mTOR inhibitors, we performed reverse phase phospho-
proteomic analysis. These data further demonstrated that AKT inhibition
by MK-2206 significantly decreased both serine (S473) and threonine
(T308) phosphorylation sites of AKT (Figure 2C , left panel ), whereas
no effect was observed on p-AKT by mTOR inhibitor (Figure 2C ,
middle panel ). The phosphorylation sites of S6RP were significantly
decreased by mTOR inhibitor but remained unaltered by AKT inhib-
itor (Figure 2C , right panel ). Together, these data suggest that AKT is
not the rate-limiting step for the activation of mTOR signaling in this
model of prostate cancer.
Simultaneous Inhibition of Both mTOR and AKT
Demonstrates Additive Antitumor Efficacy
Both AKT and mTOR are phosphorylated in a subset of human
prostate cancer. Our data show that AKT and mTOR signaling path-
ways are independently active in this model of prostate cancer (Fig-
ure 2), suggesting that simultaneous inhibition of both pathways may
result in a better therapeutic response. Tumor-bearingmice were treated
with placebo, ridaforolimus, MK-2206, or a combination of ridaforoli-
mus and MK-2206 for a duration of 9 weeks. Immunohistochemical
analysis was performed to evaluate the inhibition of p-AKT or p-S6RP
by these treatments and their effects on tumor cell proliferation. MK-
2206 alone reduced p-AKT–positive cells, while mTOR activity remains
unaffected (Figures 2 and 3A). As expected, combination treatment
with MK-2206 and ridaforolimus completely inhibited both AKT
and phospho-S6RP levels, whereas each agent alone only inhibited their
respective targets (Figures 2 and 3A). BrdU staining showed that inhib-
ition of tumor cell proliferation by either MK-2206 or mTOR inhib-
itor was further enhanced by the combination treatment (Figure 3A).
Inhibition of tumor cell proliferation by simultaneously blocking both
AKT and mTOR kinases in these tumors resulted in an increased anti-
tumor effect (Figure 3B). After 9 weeks of treatment, the tumor vol-
umes were 1366 ± 141, 618.8 ± 87, 568 ± 62, and 320 ± 75 mm3
for placebo control, MK-2206, ridaforolimus, and the combination,
respectively. These data demonstrate a significant additive antitumor
effect when mice were treated with the combination of ridaforolimus
and MK-2206 (Figure 3B) without affecting body weight (data not
Figure 3. AKT and mTOR inhibitor combinations induce an additive antitumor effect. Tumor-bearing mice were enrolled when tumor size
was 250 to 350 mm3 and randomized into four groups (n = 12 mice/group). Mice were treated with either vehicle (placebo), MK-2206 at
120 mg/kg, ridaforolimus at 1 mg/kg, or in combination for 9 weeks. (A) Mice were killed and tumors were harvested after 4 hours of the
last dose. Tumors were fixed, paraffin embedded, and sectioned. Five-micrometer-thick tumor sections were stained with hematoxylin
and eosin. Adjacent tumors sections were also stained with antibodies against p-S6RP, p-AKT (S473), or proliferation marker BrdU. Data
represented six tumors in each treatment type. Scale bar is 50 μm. (B) Tumor volume was measured by ultrasound imaging. Data were
plotted as mean ± SEM over treatment time. (C) Mice were killed and tumor weights were measured, with the mean ± SEM plotted
against treatment.
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shown). Postmortem tumor weight data further confirmed ultrasound-
based tumor volume data (Figure 3C ). Together, these data demonstrate
that the combination treatment of PTEN-deficient prostate tumors with
MK-2206 and ridaforolimus attenuates both AKT pathway and AKT-
independent mTOR pathway, leading to increased inhibition of tumor
cell proliferation and the additive antitumor efficacy.
Inhibition of AKT did not alter the activation of S6RP in the tumors
of PTEN-null prostate. To understand whether this effect is due to the
tumor microenvironment, we tested MK-2206 and ridaforolimus in an
androgen-dependent human prostate cancer cell line (LNCaP) with
loss of function of PTEN, where a negative feedback mechanism of
mTOR inhibition was observed [35–37]. Immunoblot analysis data
show the inhibition of AKT and S6RP phosphorylation by MK-2206
and ridaforolimus, respectively, and negative feedback activation of AKT
was observed by ridaforolimus (Figure 4A). Consistent with our in vivo
data, AKT inhibition had no effect on the phosphorylation of S6RP
(Figure 4A). To further investigate whether inhibition of both AKT
andmTOR results in an additive antitumor efficacy, we treated LNCaP
cells with DMSO, MK-2206, ridaforolimus, or the combination of
MK-2206 and ridaforolimus. Cell growth inhibition wasmeasured with
three different combinations of AKT andmTOR inhibitors. Cell growth
inhibition data demonstrated a significant combinational benefit in
LNCaP cells (Figure 4B). Results indicate that the combination of AKT
and mTOR inhibitors exhibits an additive to synergistic effect. These data
further confirm that AKT-independent activation ofmTOR is not limited
to the tumor microenvironment. Together, these data suggest that the
activation of mTOR is independent of AKT, and simultaneous inhibition
of AKT and mTOR induces a significant tumor growth inhibition.
Discussion
The AKT/mTOR signaling network is deregulated in more than
50% of solid tumors and plays a key role in cancer cell growth, sur-
vival, and tumor angiogenesis. PTEN is a tumor suppressor that neg-
atively regulates this pathway. Loss of function of PTEN activates
downstream substrates of PI3K signaling network in many model
systems [23]. Both AKT and mTOR are activated in human primary
prostate cancer specimens [27]. However, the dependency of AKT
and mTOR activation on tumor growth has not been dissected.
Here, we show that PTEN-deficient models of prostate cancer with
evidence of AKT and mTOR pathway activation responded to MK-
2206 and ridaforolimus combination therapy. Inhibition of either
kinase alone had no effect on the status of the other kinase (Figures 1
and 2). These findings strongly indicate that the mTOR signaling
network in the PTEN-null tumor is independent of AKT activity
and that both AKT and mTOR downstream signaling pathways play
a part in PTEN-deficient prostate tumors. These results support the
rationale for using AKT and mTOR inhibitors in combination.
Our recent publication demonstrated that this model is androgen
dependent and that androgen blockade attenuates tumor growth
Figure 4. Inhibition of AKT and mTOR exhibits combinational benefit in human prostate cancer cells. (A) LNCaP cells were treated with
DMSO, MK-2206, or ridaforolimus for 6 and 24 hours. Cells were harvested and total protein lysates were made and blotted against
indicated antibodies. (B) LNCaP cells were treated with either DMSO, MK-2206, ridaforolimus, or in combinations as indicated for 3 days.
Cells were harvested; the number of cells was counted, and percent against DMSO was calculated and plotted.
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progression [10]. In the clinic, antiandrogens or complete androgen
blockade and conventional chemotherapeutic approaches are effective
in androgen-dependent prostate cancer [38]. However, these agents do
not result in complete tumor regression and are commonly associated
with the reemergence of an aggressive and androgen therapy–resistant
form of the disease. Therefore, more effective therapeutic strategies are
needed in addition to antiandrogen therapies to prevent or delay the
emergence of castrate-resistant prostate cancer.
Recent preclinical and clinical findings suggest that AR signaling
remains critical throughout the course of the disease (reviewed in
[2]). This hypothesis has been validated by the clinical successes of
a new generation of potent AR antagonists such as MDV3100 or
antiandrogen agents such as abiraterone [2]. Recently, it has also
been demonstrated that the AR and PI3K signaling pathways are
feedback regulated in a reciprocal manner [39]. That is, androgen
independence, commonly associated with PTEN loss, is associated
with the activation PI3K signaling; conversely, PI3K inhibitors can
reactivate androgen signaling and sensitivity to antiandrogen therapy.
Here, we report MK-2206 and ridaforolimus combination efficacy
in the castrate-sensitive setting. Although robust, the antitumor response
generally resulted in tumor stasis rather than significant regression. This
finding suggests that other pathways may need to be cotargeted, such as
extracellular signal-regulated kinase (ERK)/mitogen-activated protein
kinase (MAPK) [40,41] or androgen signaling pathway. In this regard,
it would be interesting to test the MK-2206 and ridaforolimus com-
bination in both castrate-sensitive and castrate-resistant settings. It has
been shown that mTOR inhibitors reverse PI3K-mediated neoplasia
and reduce tumor volumes in genetically engineered mice models of
prostate cancer [10,13,14,43]. We and others have noted combination
benefit of ridaforolimus with anti-AR or antiandrogen inhibitors in the
partially castrate-resistant and PTEN-deficient C4-2 model (unpub-
lished data and [44]). Unfortunately, there is lack of preclinical models
available to rigorously test AKT, mTOR, and antiandrogen cotargeting
strategies in the castrate-resistant setting. Tolerability issues associated
with multidrug therapies are also a potential concern and will require
optimization of dose schedules. Nevertheless, this report provides a con-
ceptual framework for cotargeting AKT and mTOR in PTEN-deficient
prostate cancer.MK-2206 in combinationwith ridaforolimus is currently
in early phase clinical development (clinicaltrials.gov NCT01295632).
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